1. Scrip
  2. >>Focus On Asia

Roche, Sanofi Double Down On Post-Coronavirus China With Oncology Alliances

Attractions As A Rising Innovator

 
• By Brian Yang

In a bid widely seen as a move to double down on their “in China for China” strategy, Sanofi and Roche have formed new drug development alliances with local innovative players potentially worth billions.

China - Suzhou City
SUZHOU-BASED CHINESE INNOVATORS IN MNC COLLABORATIONS • Source: Shutterstock

Seizing post-coronavirus opportunities for innovative new medicines in China, multinational pharma firms are quickly moving in to support the local innovation ecosystem, a strategy underlined by the two latest big deals.

Sanofi on 9 June signed an agreement with Suzhou-based AlphaMab to develop an antibody-chemotherapy combination therapy for cancer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia